Financials data is unavailable for this security.
View more
Year on year Shandong Buchang Pharmaceuticals Co Ltd had revenues fall -11.41% from 14.95bn to 13.25bn, though the company grew net income from a loss of 1.53bn to a gain of 318.97m.
| Gross margin | 61.16% |
|---|---|
| Net profit margin | -2.99% |
| Operating margin | -0.27% |
| Return on assets | -1.62% |
|---|---|
| Return on equity | -1.68% |
| Return on investment | -2.37% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shandong Buchang Pharmaceuticals Co Ltd fell by 1.43bn. Cash Flow from Investing was negative at 168.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 195.61m for operations while cash used for financing totalled 1.07bn.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 10.46 |
|---|---|
| Tangible book value per share | 6.91 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.28 |
|---|---|
| Quick ratio | 0.5242 |
| Total debt/total equity | 0.3721 |
|---|---|
| Total debt/total capital | 0.2763 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share fell -86.88% while earnings per share excluding extraordinary items rose 120.85%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 3.42% |
|---|---|
| Div growth rate (5 year) | -36.72% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -29.48 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 87.78 |
More ▼
